A double-blind, placebo-controlled, dose-finding, phase 2 study to assess the safety, tolerability, and immunogenicity of three dose levels of ACAM3000 modified vaccinia Ankara smallpox vaccine in adults with and without previous smallpox vaccination
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2014
At a glance
- Drugs MVA 3000 (Primary)
- Indications Smallpox
- Focus Pharmacodynamics
- Sponsors sanofi pasteur
- 22 Jun 2007 Status change from in progress to completed.
- 08 Nov 2005 New trial record.